Sandoz standalone

It is all change at Sandoz this year, as Novartis has executed a 180-degree strategy shift. No longer is it pursuing its previous policy of ever closer union with the innovative pharma division, but instead it now favours far greater autonomy for its generic…

Read More

The changing of the guard: New CEOs move in

Recent months have seen a slew of management changes at major generics companies. Some of this has been driven by shareholder dissatisfaction with poor performance (Teva being the obvious example here), but there have also been generational and other shifts that offer interesting pointers…

Read More

Oy Vey, Teva!

Things appear to be going from bad to worse at Teva, which is giving the strong impression of being in meltdown. One can only hope that the recent Q2 results, which featured an eye-watering $6.1bn write-down of the company’s recently-acquired Actavis generics assets, mark…

Read More

Biosimilars: The five stages of grief

According to the Swiss psychiatrist Elisabeth Kübler-Ross, grief has five stages: denial, anger, bargaining, depression and acceptance. Although the development of biosimilars should not be an inherently grief-stricken business, it nevertheless appears to be closely following this path, certainly from the perspective of the…

Read More

Goodness gracious me! Time for a management change at Teva

 

The news earlier this week that Siggi Olafsson is leaving Teva, to be succeeded by Dipankar Bhattacharjee (currently head of Teva Generics Europe) comes as something of a surprise, to say the least. As the architect of Teva’s long drawn-out purchase of Allergan’s generics…

Read More

Hartmut Retzlaff falls victim to barbarian hordes

The announcement today that Hartmut Retzlaff has stepped down as CEO of Stada ‘due to a serious long-term illness’ comes as something of a surprise, but the reasons are not hard to discern. For weeks, activist investors in the form of a group called…

Read More